Please use this identifier to cite or link to this item: http://sgc.anlis.gov.ar/handle/123456789/1467
Title: Effects of artesunate against Trypanosma cruzi
Authors: Olivera, Gabriela Carina 
Postan, Miriam 
González, Mariela Natacha 
Keywords: Enfermedad de Chagas;Artesunato;Quimioterapia;Trypanosoma cruzi
Issue Date: Sep-2015
Journal: Experimental parasitology 
Abstract: 
Therapy against Trypanosma cruzi relies on only two chemically related nitro-derivative drugs, benznidazole and nifurtimox, both limited by poor efficacy and toxicity. It is suspected that with prolonged usage of these drugs, resistant parasites will be selected, which results in risk for treatment failure over the time. Herein, we studied the in vitro activity of artesunate, the most effective drug to treat severe P. falciparum and chloroquine-resistant P. vivax, on three strains of T. cruzi originated in different regions of Latin America (Argentina, Nicaragua and Brazil). The results of these assays showed that artesunate inhibits multiplication of epimastigotes (IC50 = 50, 6.10 and 23 µM, respectively) and intracellular amastigotes (IC50 = 15, 0.12 and 6.90 µM, respectively), indicating that it represents a potent anti-T. cruzi compound in terms of inhibiting parasite multiplication in vitro. We then tested the effect of artesunate in Balb/c mice infected with Brazil strain and found that it failed to cure the infection, suggesting that the drug may be unsuitable for in vivo treatment. When infected mice were treated with high doses AS + BZ, the outcome of infection was similar to that observed in mice treated with BZ alone. Nevertheless, understanding of structure-activity relationship of artesunate might lead to the development of new and effective drugs against T. cruzi.
URI: http://sgc.anlis.gob.ar/handle/123456789/1467
DOI: 10.1016/j.exppara.2015.05.014
Appears in Collections:Publicaciones INP

Show full item record

Page view(s)

4
checked on Jul 4, 2020

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.